Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Aug 30, 2023 (filed on Sep 01, 2023)Insider Name:Johnson Laura L.Ownership Type:Direct OwnershipSecurities:Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:8,500Price:--
-
Aug 30, 2023 (filed on Sep 01, 2023)Insider Name:Hoffman Robert E.Ownership Type:Direct OwnershipSecurities:Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:23,142Price:--
-
Aug 30, 2023 (filed on Sep 01, 2023)Insider Name:Toth Robert Joseph JrOwnership Type:Direct OwnershipSecurities:Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:8,500Price:--
-
Aug 30, 2023 (filed on Sep 01, 2023)Insider Name:Favorito Tamara AOwnership Type:Direct OwnershipSecurities:Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:8,500Price:--
-
Aug 30, 2023 (filed on Sep 01, 2023)Insider Name:Brown Dennis MOwnership Type:Direct OwnershipSecurities:Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:10,175Price:--
-
Jun 01, 2023 (filed on Jun 02, 2023)Insider Name:Hoffman Robert E.Ownership Type:Direct OwnershipSecurities:Common Stock, par value $0.001 per shareNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:59,800Price:--
Filings by filing date
-
Aug 30, 2023 (filed on Sep 01, 2023)Insider Name:Johnson Laura L.Ownership Type:Direct OwnershipSecurities:Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:8,500Price:--
-
Aug 30, 2023 (filed on Sep 01, 2023)Insider Name:Hoffman Robert E.Ownership Type:Direct OwnershipSecurities:Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:23,142Price:--
-
Aug 30, 2023 (filed on Sep 01, 2023)Insider Name:Toth Robert Joseph JrOwnership Type:Direct OwnershipSecurities:Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:8,500Price:--
-
Aug 30, 2023 (filed on Sep 01, 2023)Insider Name:Favorito Tamara AOwnership Type:Direct OwnershipSecurities:Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:8,500Price:--
-
Aug 30, 2023 (filed on Sep 01, 2023)Insider Name:Brown Dennis MOwnership Type:Direct OwnershipSecurities:Options (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:10,175Price:--
-
Jun 01, 2023 (filed on Jun 02, 2023)Insider Name:Hoffman Robert E.Ownership Type:Direct OwnershipSecurities:Common Stock, par value $0.001 per shareNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:59,800Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 9920 Pacific Heights Blvd Suite 150, Suite 200 SAN DIEGO CA 92121 |
Tel: | N/A |
Website: | https://www.kintara.com |
IR: | See website |
Key People | ||
Robert E. Hoffman Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer | John Liatos Senior Vice President, Business Development |
Business Overview |
Kintara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of new cancer therapies. It is focused on the development of novel cancer therapies for patients with unmet medical needs. Its two candidates include VAL-083 and REM-001. VAL-083 is a novel, validated, deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC), and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC), basal cell carcinoma nevus syndrome (BCCNS), and access graft failure in hemodialysis patients. VAL-083 is being evaluated in all three GBM patient subtypes in the GBM AGILE Study: newly diagnosed methylated MGMT; newly diagnosed unmethylated MGMT, and recurrent. |
Financial Overview |
For the six months ended 31 December 2023, Kintara Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders decreased 51% to $4.2M. Lower net loss reflects Research and Development decrease of 62% to $1.9M (expense), General and administration - gross decrease of 20% to $1.8M (expense), Stock-based Compensation in SGA decrease of 66% to $232K (expense). |
Employees: | 2 as of Jun 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $15.76M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$10.57M as of Dec 31, 2023 |
Net annual income (TTM): | -$10.77M as of Dec 31, 2023 |
Free cash flow (TTM): | -$6.80M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 39,037,899 as of Feb 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |